Blog

DEEP RESEARCH · CHINESE BIOTECH / MERITZ ON

Chinese Biotech — Meritz On Video Bookmark

A viewing-note post that bookmarks a single Meritz Securities “Meritz On” video on the Chinese biotech industry.

Published: 2025-12-04 · Industry review · Original Naver Blog post

Investment decisions are your responsibility. This material is research, not a recommendation to buy or sell.

0. Bottom line first

This post is a “viewing-note” bookmark: the source page contains no written analysis from me — only an embed of one Meritz Securities (Meritz On) video about the Chinese biotech industry. On this page I only collect the video link and a short viewing guide. I deliberately do not copy specific company names, numbers, or forecasts from the video into this page; please watch the video directly for those details.

1. What this post actually contains

Official fact: The source Naver Blog post embeds exactly one external resource — the YouTube video https://youtube.com/watch?v=h7BmbM1jLwY. There is no additional body text, table, attachment, or chart in the original post.

Interpretation: I normally publish long, self-authored single-stock or industry reports, but I also keep short “bookmark posts” for useful industry videos. This post falls into that bookmark category. So the value here is in the video itself, not in any commentary on this page — this page is just a fast entry point to the video.

SOURCE

Meritz On video

The entire body is a single video from “Meritz On,” the research-content channel of Meritz Securities, focused on Chinese biotech.

FORMAT

Bookmark-style post

No author commentary or summary; just an embed, treated as a reference bookmark.

SCOPE

Topic: Chinese biotech

Industry-level coverage; for specific names and numbers, please watch the video directly.

2. How I personally watch Chinese-biotech videos

Since the original post carries no written analysis, I only add a light personal checklist for watching this kind of industry video. This is not a transcription of the video — it is the lens I tend to apply.

  • What time window the video covers (licensing cycle, clinical-data season) and when it was recorded
  • Which Chinese biotech categories (ADC, bispecifics, CAR-T, GLP-1, etc.) the speaker emphasizes
  • How the global-pharma licensing flow into and out of China is framed
  • The speaker’s tone on China domestic pricing and regulation (cautious or constructive)
  • Any mention of Korean ADC/antibody companies as competitors or partners

Interpretation: These bullets describe how I view such videos, not what the video itself claims. For the actual arguments and numbers, please watch the video.

3. Next step

If I later publish a dedicated, self-authored analysis of the Chinese biotech industry, I plan to update this page or add a cross-link. For now, the YouTube link in the Sources block below is the primary material.

Sources

Naver original